Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 23;9(1):ofab620.
doi: 10.1093/ofid/ofab620. eCollection 2022 Jan.

Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort Study

Noah Wald-Dickler  1   2 , Todd C Lee  3 , Soodtida Tangpraphaphorn  1 , Susan M Butler-Wu  1   4 , Nina Wang  1 , Tyler Degener  1   2 , Carolyn Kan  1   2 , Matthew C Phillips  1   2 , Edward Cho  1   2 , Catherine Canamar  1 , Paul Holtom  1   2 , Brad Spellberg  1
Affiliations

Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort Study

Noah Wald-Dickler et al. Open Forum Infect Dis. .

Abstract

Background: We sought to determine the comparative efficacy of fosfomycin vs ertapenem for outpatient treatment of complicated urinary tract infections (cUTIs).

Methods: We conducted a multicenter, retrospective cohort study involving patients with cUTI treated with outpatient oral fosfomycin vs intravenous ertapenem at 3 public hospitals in Los Angeles County between January 2018 and September 2020. The primary outcome was resolution of clinical symptoms 30 days after diagnosis.

Results: We identified 322 patients with cUTI treated with fosfomycin (n = 110) or ertapenem (n = 212) meeting study criteria. The study arms had similar demographics, although patients treated with ertapenem more frequently had pyelonephritis or bacteremia while fosfomycin-treated patients had more retained catheters, nephrolithiasis, or urinary obstruction. Most infections were due to extended-spectrum β-lactamase-producing E. coli and Klebsiella pneumoniae, 80%-90% of which were resistant to other oral options. Adjusted odds ratios for clinical success at 30 days, clinical success at last follow-up, and relapse were 1.21 (95% CI, 0.68-2.16), 0.84 (95% CI, 0.46-1.52), and 0.94 (95% CI, 0.52-1.70) for fosfomycin vs ertapenem, respectively. Patients treated with fosfomycin had significant reductions in length of hospital stay and length of antimicrobial therapy and fewer adverse events (1 vs 10). Fosfomycin outcomes were similar irrespective of duration of lead-in intravenous (IV) therapy or fosfomycin dosing interval (daily, every other day, every third day).

Conclusions: These results would support the conduct of a randomized controlled trial to verify efficacy. In the meantime, they suggest that fosfomycin may be a reasonable stepdown from IV antibiotics for cUTI.

Keywords: complicated urinary tract infections; ertapenem; fosfomycin.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patient selection flowchart. Abbreviation: EMR, electronic medical record; UTI, urinary tract infection.
See this image and copyright information in PMC

References

    1. Spellberg B, Doi Y.. The rise of fluoroquinolone-resistant Escherichia coli in the community: scarier than we thought. J Infect Dis 2015; 212:1853–5. - PMC - PubMed
    1. Doi Y, Park YS, Rivera JI, et al. . Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013; 56:641–8. - PMC - PubMed
    1. Lob SH, Nicolle LE, Hoban DJ, Kazmierczak KM, Badal RE, Sahm DF.. Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010–2014. Diagn Microbiol Infect Dis 2016; 85:459–65. - PubMed
    1. Jernigan JA, Hatfield KM, Wolford H, et al. . Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012–2017. N Engl J Med 2020; 382:1309–19. - PMC - PubMed
    1. Ben-Ami R, Schwaber MJ, Navon-Venezia S, et al. . Influx of extended-spectrum beta-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis 2006; 42:925–34. - PubMed